Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis

eLife

Volumn 2014, Issue 3, 2014, Pages

  Dixon, Scott J ^a,d   Patel, Darpan ^a   Welsch, Matthew ^a   Skouta, Rachid ^a   Lee, Eric ^a   Hayano, Miki ^a   Thomas, Ajit G ^b   Gleason, Caroline ^a   Tatonetti, Nicholas ^a   Slusher, Barbara S ^b,c   Stockwell, Brent R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Departments of Neurology and Psychiatry   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Cystine; Erastin; Reactive oxygen species; SLC7A11; Sorafenib

Indexed keywords

ANTIPORTER; CYSTINE; DACTINOMYCIN; DASATINIB; ERLOTINIB; GEFITINIB; GLUTAMIC ACID; IMATINIB; LAPATINIB; PACLITAXEL; QUINAZOLINONE DERIVATIVE; SORAFENIB; SUNITINIB; TRANSCRIPTOME; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; AMINO ACID TRANSPORTER; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; ERASTIN; IRON; NICOTINAMIDE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LETHALITY; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; CELL SEPARATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

20-HYDROXYSTEROID DEHYDROGENASES; AMINO ACID TRANSPORT SYSTEM Y+; APOPTOSIS; BIOMARKERS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CYSTINE; ENDOPLASMIC RETICULUM STRESS; GLUTAMIC ACID; HUMANS; IRON; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; SEQUENCE ANALYSIS, RNA; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTOME; UP-REGULATION;

EID: 84901323900     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.02523     Document Type: Article

References (66)

1. Agyeman, A. S., Chaerkady, R., Shaw, P. G., Davidson, N. E., Visvanathan, K., Pandey, A., Kensler, T. W. 2012. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat, 132, 175-87.
2. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., Peterson, J. R. 2011. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology, 29, 1039-45.
3. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., et al. 2005. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 92, 1855-61.
4. Banjac, A., Perisic, T., Sato, H., Seiler, A., Bannai, S., Weiss, N., Kolle, P., et al. 2008. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene, 27, 1618-28.
5. Buckingham, S. C., Campbell, S. L., Haas, B. R., Montana, V., Robel, S., Ogunrinu, T., Sontheimer, H. 2011. Glutamate release by primary brain tumors induces epileptic activity. Nature medicine, 17, 1269-74.
6. Burczynski, M. E., Sridhar, G. R., Palackal, N. T., Penning, T. M. 2001. The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha, beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem, 276, 2890-7.
7. Chintala, S., Li, W., Lamoreux, M. L., Ito, S., Wakamatsu, K., Sviderskaya, E. V., Bennett, D. C., et al. 2005. Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 102, 10964-9.
8. Conrad, M., Sato, H. 2012. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids, 42, 231-46.
9. Coriat, R., Nicco, C., Chereau, C., Mir, O., Alexandre, J., Ropert, S., Weill, B., et al. 2012. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther, 11, 2284-93.
10. Dai, Z., Huang, Y., Sadee, W., Blower, P. 2007. Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc. Journal of medicinal chemistry, 50, 1896-906.
11. De Bundel, D., Schallier, A., Loyens, E., Fernando, R., Miyashita, H., Van Liefferinge, J., Vermoesen, K., et al. 2011. Loss of system x(c)-does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci, 31, 5792-803.
12. Desoize, B., Jardillier, J. 2000. Multicellular resistance: a paradigm for clinical resistance? Critical reviews in oncology/hematology, 36, 193-207.
13. Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., et al. 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149, 1060-72.
14. Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Thomas, A. G., Gleason, C., Tatonetti, N., Slusher, B. S., Stockwell, B. R. 2014. Data from: Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Dryad Digital Repository. doi:10.5061/dryad.jp43c
15. Dixon, S. J., Stockwell, B. R. 2013. The role of iron and reactive oxygen species in cell death. Nat Chem Biol, 10, 9-17.
16. Dolma, S., Lessnick, S. L., Hahn, W. C., Stockwell, B. R. 2003. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 3, 285-96.
17. Eden, E., Navon, R., Steinfeld, I., Lipson, D., Yakhini, Z. 2009. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC bioinformatics, 10, 48.
18. Friedrich, J., Seidel, C., Ebner, R., Kunz-Schughart, L. A. 2009. Spheroid-based drug screen: considerations and practical approach. Nature protocols, 4, 309-24.
19. Gargalovic, P. S., Imura, M., Zhang, B., Gharavi, N. M., Clark, M. J., Pagnon, J., Yang, W. P., et al. 2006. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A, 103, 12741-6.
20. Gorrini, C., Harris, I. S., Mak, T. W. 2013. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov, 12, 931-47.
21. Gout, P. W., Buckley, A. R., Simms, C. R., Bruchovsky, N. 2001. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U. K, 15, 1633-40.
22. Hamacher-Brady, A., Stein, H. A., Turschner, S., Toegel, I., Mora, R., Jennewein, N., Efferth, T., et al. 2011. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem, 286, 6587-601.
23. Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., et al. 2003. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular Cell, 11, 619-33.
24. Hediger, M. A., Clemencon, B., Burrier, R. E., Bruford, E. A. 2013. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med, 34, 95-107.
25. Holohan, C., Van Schaeybroeck, S., Longley, D. B., Johnston, P. G. 2013. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer, 13, 714-26.
26. Ishii, T., Bannai, S., Sugita, Y. 1981. Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. The Journal of biological chemistry, 256, 12387-92.
27. Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., et al. 2011. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell, 19, 387-400.
28. Jaramillo, M. C., Zhang, D. D. 2013. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev, 27, 2179-91.
29. Jiang, H. Y., Wek, S. A., McGrath, B. C., Lu, D., Hai, T., Harding, H. P., Wang, X., et al. 2004. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol, 24, 1365-77.
30. Jung, K. A., Kwak, M. K. 2013. Enhanced 4-hydroxynonenal resistance in KEAP1 silenced human colon cancer cells. Oxid Med Cell Longev, 2013, 423965.
31. Kakazu, E., Ueno, Y., Kondo, Y., Inoue, J., Ninomiya, M., Kimura, O., Wakui, Y., et al. 2011. Plasma L-cystine/L-glutamate imbalance increases tumor necrosis factor-alpha from CD14+ circulating monocytes in patients with advanced cirrhosis. PLoS ONE, 6, e23402.
32. Katz, S. I., Zhou, L., Chao, G., Smith, C. D., Ferrara, T., Wang, W., Dicker, D. T., et al. 2009. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer biology & therapy, 8, 2406-16.
33. Kim, Y. S., Jin, H. O., Seo, S. K., Woo, S. H., Choe, T. B., An, S., Hong, S. I., et al. 2011. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol, 82, 216-26.
34. Kumar, A., Tikoo, S., Maity, S., Sengupta, S., Kaur, A., Kumar Bachhawat, A. 2012. Mammalian proapoptotic factor ChaC1 and its homologues function as gamma-glutamyl cyclotransferases acting specifically on glutathione. EMBO reports, 13, 1095-101.
35. Lee, J. I., Dominy, J. E., Jr., Sikalidis, A. K., Hirschberger, L. L., Wang, W., Stipanuk, M. H. 2008. HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway. Physiological genomics, 33, 218-29.
36. Lillig, C. H., Lonn, M. E., Enoksson, M., Fernandes, A. P., Holmgren, A. 2004. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proceedings of the National Academy of Sciences of the United States of America, 101, 13227-32.
37. Lou, H., Du, S., Ji, Q., Stolz, A. 2006. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. Mol Pharmacol, 69, 1662-72.
38. Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J. C., Maziere, J. C., Chauffert, B., Galmiche, A. 2013. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer, 133, 1732-42.
39. Lowinger, T. B., Riedl, B., Dumas, J., Smith, R. A. 2002. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des, 8, 2269-78.
40. Mungrue, I. N., Pagnon, J., Kohannim, O., Gargalovic, P. S., Lusis, A. J. 2009. CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol, 182, 466-76.
41. Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H., Sohda, S., Hamada, H., et al. 2003. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. British journal of cancer, 88, 951-6.
42. Panka, D. J., Wang, W., Atkins, M. B., Mier, J. W. 2006. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res, 66, 1611-9.
43. Rahmani, M., Davis, E. M., Bauer, C., Dent, P., Grant, S. 2005. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. The Journal of biological chemistry, 280, 35217-27.
44. Rahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., Grant, S. 2007. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Molecular and Cellular Biology, 27, 5499-513.
45. Robe, P. A., Martin, D. H., Nguyen-Khac, M. T., Artesi, M., Deprez, M., Albert, A., Vanbelle, S., et al. 2009. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC cancer, 9, 372.
46. Sato, H., Shiiya, A., Kimata, M., Maebara, K., Tamba, M., Sakakura, Y., Makino, N., et al. 2005. Redox imbalance in cystine/glutamate transporter-deficient mice. The Journal of biological chemistry, 280, 37423-9.
47. Sato, H., Tamba, M., Ishii, T., Bannai, S. 1999. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. The Journal of biological chemistry, 274, 11455-8.
48. Shukla, K., Thomas, A. G., Ferraris, D. V., Hin, N., Sattler, R., Alt, J., Rojas, C., et al. 2011. Inhibition of xc(-) transporter-mediated cystine uptake by sulfasalazine analogs. Bioorganic & medicinal chemistry letters, 21, 6184-7.
49. Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., et al. 2014. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc, 136, 4551-6.
50. Stein, M. N., Flaherty, K. T. 2007. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res, 13, 3765-70.
51. Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., et al. 2005. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23, 965-72.
52. Tatonetti, N. P., Ye, P. P., Daneshjou, R., Altman, R. B. 2012. Data-driven prediction of drug effects and interactions. Sci Transl Med, 4, 125ra31.
53. Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padro, M., Daemen, A., Hu, M., et al. 2013. Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target. Cancer Cell, 24, 450-65.
54. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., et al. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 10, 241-52.
55. Trapnell, C., Pachter, L., Salzberg, S. L. 2009. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-11.
56. Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., et al. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnology, 28, 511-5.
57. Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Jones, C. M., et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116, 855-67.
58. Welsch, M. E., Snyder, S. A., Stockwell, B. R. 2010. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol, 14, 347-61.
59. Whitney, M. L., Jefferson, L. S., Kimball, S. R. 2009. ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun, 379, 451-5.
60. Wilcken, R., Liu, X., Zimmermann, M. O., Rutherford, T. J., Fersht, A. R., Joerger, A. C., Boeckler, F. M. 2012. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. Journal of the American Chemical Society, 134, 6810-8.
61. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., et al. 2006. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, 835-44.
62. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., Lynch, M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular cancer therapeutics, 7, 3129-40.
63. Wolpaw, A. J., Shimada, K., Skouta, R., Welsch, M. E., Akavia, U. D., Pe'er, D., Shaik, F., et al. 2011. Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci U S A, 108, E771-80.
64. Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G. J., Wada, T., et al. 2012. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nature communications, 3, 883.
65. Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., et al. 2007. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature, 447, 864-8.
66. Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., et al. 2014. Regulation of ferroptotic cancer cell death by GPX4. Cell, 156, 317-31.